H1N1 Vaccine Global Market Report 2024

The global h1n1 vaccine market has grown strongly in recent years. It will grow from $3.16 billion in 2023 to $3.37 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. Historical growth can be attributed to past influenza outbreaks, heightened concerns about global health security, advancements in vaccine development and approval processes, the implementation of global vaccination campaigns, educational initiatives for public health, government funding and subsidies, and the pharmaceutical industry's adaptability and responsiveness.

The global H1N1 vaccine market is expected to see strong growth in the next few years. It will grow to $4.46 billion in 2028 at a compound annual growth rate (CAGR) of 7.2%. The anticipated growth in the forecast period is driven by research into broad-spectrum vaccines, initiatives aimed at global vaccine equity, efforts to build resilience in public health systems, strengthening global health governance, and the integration of H1N1 vaccination with routine immunization programs. Major trends expected during this period encompass preparedness for global pandemics, ongoing influenza vaccination programs, advancements in vaccine development, research into cross-protection, global health initiatives, technological improvements in vaccine manufacturing, expansion of production capacities, and the enhancement of data monitoring and surveillance within the field of vaccination and public health.

Increased expenditure in immunology and vaccine R&D is driving H1N1 vaccine market growth. Immunology and vaccines, integral in preventing infections and bolstering antibody production, receive significant research focus. Notably, global governments invested $94.11 billion (€93 billion) in vaccine and treatment development within 11 months since the pandemic onset, with 95% coming from the public sector, primarily allocated to vaccination development, fostering the H1N1 vaccine market.

The surge in international travel is a catalyst for the H1N1 vaccine market. International travel, involving cross-border movement for tourism, business, and more, demands H1N1 vaccination as a preventive measure. Nations and global bodies recommend or mandate H1N1 vaccination to curb virus transmission during travel. International tourism receipts hitting $1 trillion in 2022 and reaching 64% of pre-pandemic levels signify the market's growth fueled by increased travel safety measures.

Strategic collaborations are shaping the H1N1 vaccine market landscape. Companies forge partnerships to amplify market presence. An example is the $123 million agreement between A significant and hVIVO to create an H1N1 influenza challenge virus, boosting growth potential for both entities in the industry.

Innovations like needle-free nasal vaccines propel the H1N1 vaccine market. Needle-free nasal vaccines, devoid of traditional needles or syringes, offer a painless, non-invasive immunization method, predominantly through nasal administration. Nasovac S4, launched by Serum Institute and Mylab in October 2023, targets H1N1 and H3N2 viruses, stimulating immune response in individuals aged 2 and above against influenza strains A and B, underscoring market sustainability and product advancements.

In July 2023, Sinovac Biotech Ltd., a prominent biopharmaceutical company based in China, forged a strategic partnership with Bio Farma, a state-owned biopharmaceutical company based in Indonesia, for an undisclosed investment. This alliance is designed to cater to Indonesia's domestic vaccine market while targeting expansion into the international sphere. The collaboration between Sinovac and Bio Farma is aimed at facilitating Sinovac's introduction of upcoming products, such as varicella, influenza, and pneumococcal polysaccharide vaccines. These initiatives are intended to address the healthcare needs of the region effectively and contribute to the enhancement of local and national public health initiatives. Bio Farma is an Indonesia-based state-owned biopharmaceutical company, operating in various vaccine markets, including H1N1.

Major companies operating in the h1n1 vaccine market report are Sanofi SA, Novartis AG, GlaxoSmithKline PLC, CSL Limited, AstraZeneca Inc., Zydus Lifesciences Limited, Merck and Co.Inc., Novavax Inc., Baxter Laboratories Inc., Panacea Biotec Ltd., Sinovac Biotech Ltd., Green Cross Corp., Abbott Laboratories, Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, Seqirus Ltd., Cipla Inc., Protein Sciences Corporation, Hualan Biological Engineering Inc., Changsheng Bio-Technology Co. Ltd., Takeda Pharmaceutical Ltd., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Bio Farma Group, PT Kalbe Farma Tbk, Daiichi Sankyo Chemical Pharma Co. Ltd., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Moderna Inc., CureVac NV, BioNTech SE, Inovio Pharmaceuticals Inc., Vaxart Inc., Altimmune Inc., Dynavax Technologies Corporation, VBI Vaccines Inc., and GeoVax Labs Inc.

North America was the largest region in the H1N1 vaccine market in 2023. The regions covered in the h1n1 vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the h1n1 vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary product types for H1N1 vaccines include inactivated and live attenuated vaccines. Inactivated vaccines within the market are formulated to prevent diseases caused by the influenza H1N1 virus. They consist of synthetic vaccines with protective immunizing properties, containing hemagglutinin (HA) antigens derived from four inactivated influenza viruses, encompassing two distinct influenza type A strains and two different influenza type B strains. These vaccines are administered through various routes such as intradermal, intramuscular, and subcutaneous methods, and they are utilized across hospitals, clinics, research and diagnostic laboratories, among other medical settings.

The H1N1 vaccine market report is one of a series of new reports provides H1N1 vaccine market statistics, including H1N1 vaccine industry global market size, regional shares, competitors with an H1N1 vaccine market share, detailed H1N1 vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the H1N1 vaccine industry. This H1N1 vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The H1N1 vaccines market consists of sales of TIV (flu shot (injection) and LAIV (nasal spray (mist) of live attenuated influenza vaccine). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.